|
Jun 26
|
Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
|
|
Jun 26
|
Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
|
|
May 9
|
Savara Reports First Quarter 2024 Financial Results and Provides Business Update
|
|
May 7
|
Savara to Present at the Citizens JMP Life Sciences Conference
|
|
Dec 1
|
Savara Inc. (NASDAQ:SVRA) most popular amongst private equity firms who own 41% of the shares, institutions hold 31%
|